Sparsentan

Sparsentan
Names
Trade namesFilspari
Clinical data
Drug classEndothelin and angiotensin II receptor blocker[1]
Main usesPrimary immunoglobulin A nephropathy.[1]
Side effectsLow blood pressure, swelling of the legs, high potassium, low red blood cells, liver problems[1]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		By mouth
Typical dose200 to 400 mg OD[1]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status

Sparsentan, sold under the brand name Filspari, is a medication used to treat primary immunoglobulin A nephropathy.[1] Specifically it is used to reduce protein in the urine.[1] As of 2023, it is unclear if it affects long term kidney function.[1] It is taken by mouth.[1]

Common side effects include low blood pressure, swelling of the legs, high potassium, and low red blood cells.[1] Severe side effects may include liver problems.[1] Use in pregnancy may harm the baby.[1] It is an endothelin and angiotensin II receptor blocker.[1]

Sparsentan was approved for medical use in the United States in 2023.[1] It is estimated to cost about 170,000 USD per year in the United States as of 2023.[2]

Medical uses

Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.[1]

Dosage

It is started at 200 mg once per day and is increased to 400 mg once per day after two weeks.[1]

Society and culture

Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria.[1]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 "Filspari- sparsentan tablet, film coated". DailyMed. 17 February 2023. Archived from the original on 7 March 2023. Retrieved 6 March 2023.
  2. ↑ "February 2023 decisions expected from the FDA". Prime Therapeutics LLC. Archived from the original on 27 January 2023. Retrieved 24 May 2023.
Identifiers:
  • Clinical trial number NCT03762850 for "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.